Mersana Therapeutics, Inc. Stock News

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics, Inc. (NasdaqGS: MRSN) to Day One Biopharmaceuticals, Inc. Under the terms of the proposed transaction, shareholders of Mersana will receive $25.00 per share in cash plus one n...

Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Michael Vasconcelles - Head of Research & Development Charles York - COO & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Gr...

MILWAUKEE , Nov. 13, 2025 /PRNewswire/ -- The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Day One Biopharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it for up to $285 million.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive...

Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Frida...

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice President of Investor Relations & Corporate Communications Martin H.